NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.388) was uploaded to the NHS England Website on Monday 9, March 2026.
The following changes have been introduced:
Glofitamab in combinaton with gemcitabine and oxaliplatin (GLO2)
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B- cell lymphoma where the following criteria have been met
Moved into routine commissioning - section B of list
Talquetamab monotherapy (TALQ1)
For treating relapsed or refractory multiple myeloma after 3 or more treatments where the following criteria have been met
Moved into routine commissioning - section B of list
Nivolumab (NIV25) ## Nivolumab (NIV25)
Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met
Moved into routine commissioning - section B of list; Treatment criteria (#9) updated Treatment criteria (#9) updated
Durvalumab with gemcitabine and cisplatin (DUR8)
For neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer where the following criteria have been met
Date moving into routine commissioning updated
Bevacizumab with FIRST LINE fluoropyrimidine-based chemotherapy (BEV11)
For metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met
‘TA’ and ‘Date of Final NICE Guidance’ columns updated
Nivolumab (NIV25) ## Nivolumab (NIV25)
Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met Nivolumab plus ipilimumab for previously untreated patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met
Moved into routine commissioning - section B of list; Treatment criteria (#9) updated Treatment criteria (#9) updated
Pembrolizumab (PEMB9a)
Pembrolizumab monotherapy for treating unresectable or advanced malignant melanoma (form a): REGISTRATION OF START OF PEMBROLIZUMAB MONOTHERAPY OR OF PREVIOUSLY COMMENCED AND CURRENTLY CONTINUED PEMBROLIZUMAB MONOTHERAPY This form comes in 3 parts. 1. The first part is for patients who are either scheduled to commence pembrolizumab monotherapy or who commenced and continue to receive pembrolizumab monotherapy. 2. The second part of the form which must use the same unique Blueteq identifier is for those benefitting patients who choose to electively discontinue pembrolizumab after 2 or more years of treatment; this second part (patient details be automatically entered) will only appear once the first part of the form is approved and should be completed at the time of elective discontinuation of pembrolizumab. 3. The third part of the form which must use the same unique Blueteq identifier is for those patients registered as having electively and previously stopped pembrolizumab and in whom there is disease progression for which the clinician wishes to re-commence pembrolizumab; this third part of the form (patient details will automatically entered) will only appear once second part of the form has been approved.
Treatment criteria (#9) updated
Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy (PEMB15)
For previously untreated advanced oesophageal carcinoma which expresses PD-L1 with a combined positive score of 10 or more where the following criteria have been met
Treatment criterion (#9, 10 and 12) updated; Treatment criterion (#2 and 13) removed
Pembrolizumab in combination with lenvatinib (PEMB23)
For the treatment of patients with endometrial carcinoma who have progressive disease during or following prior platinum-containing therapy given any setting for advanced or recurrent or metastatic disease and who are not candidates for potentially curative surgery or radiotherapy or chemoradiotherapy where the following criteria have been met
Treatment criterion (#8, 9, 10, 11, 13 and 15) updated; Treatment criterion (#2, 10 and 17) removed